GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » 3-Year ROIIC %

Sio Gene Therapies (Sio Gene Therapies) 3-Year ROIIC % : 0.00% (As of Mar. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Sio Gene Therapies 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Sio Gene Therapies's 3-Year ROIIC % for the quarter that ended in Mar. 2022 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Sio Gene Therapies's 3-Year ROIIC % or its related term are showing as below:

SIOX's 3-Year ROIIC % is not ranked *
in the Biotechnology industry.
Industry Median: -15.155
* Ranked among companies with meaningful 3-Year ROIIC % only.

Sio Gene Therapies 3-Year ROIIC % Historical Data

The historical data trend for Sio Gene Therapies's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sio Gene Therapies 3-Year ROIIC % Chart

Sio Gene Therapies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
3-Year ROIIC %
Get a 7-Day Free Trial - 21.60 453.36 -3,986.38 -205.21

Sio Gene Therapies Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -205.21 - - -

Competitive Comparison of Sio Gene Therapies's 3-Year ROIIC %

For the Biotechnology subindustry, Sio Gene Therapies's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sio Gene Therapies's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Sio Gene Therapies's 3-Year ROIIC % falls into.



Sio Gene Therapies 3-Year ROIIC % Calculation

Sio Gene Therapies's 3-Year ROIIC % for the quarter that ended in Mar. 2022 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -71.8196232 (Mar. 2022) - -127.145018 (Mar. 2019) )/( 6.243 (Mar. 2022) - 33.203 (Mar. 2019) )
=55.3253948/-26.96
=-205.21%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Sio Gene Therapies  (OTCPK:SIOX) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Sio Gene Therapies 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sio Gene Therapies (Sio Gene Therapies) Business Description

Traded in Other Exchanges
N/A
Address
130 West 42nd Street, 26th Floor, New York, NY, USA, 10036
Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.
Executives
Parag V Meswani officer: Chief Commercial Officer 130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu officer: Chief Executive Officer C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif officer: Principal Financial Officer C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo 10 percent owner C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado 10 percent owner 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901

Sio Gene Therapies (Sio Gene Therapies) Headlines